title: [Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy].
abstract: OBJECTIVE
  To analyze the impact of platelet count on the prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy.
  
  
  METHODS
  Clinical and follow-up data of 286 patients with stage II-III colorectal cancer receiving adjuvant FOLFOX chemotherapy from March 2003 to October 2011 were analyzed retrospectively. Associations of baseline blood platelet count before chemotherapy and nadir blood platelet count during chemotherapy with relapse and death after adjuvant chemotherapy were analyzed by ROC curve and the optimal cutoff was selected. The association of the blood platelet count and the prognosis was analyzed by Kaplan-Meier and Cox regression model.
  
  
  RESULTS
  ROC curve showed the baseline blood platelet count was associated with recurrence (AUC=0.588, P=0.034). The optimal cutoff affecting recurrence was 276×10(9)/L. Kaplan-Meier showed those with baseline platelet count >276×10(9)/L receiving adjuvant chemotherapy had worse disease free survival (DFS) than those with baseline platelet count ≤276×10(9)/L, whose 5-year disease free survival(DFS) was 66% and 80% respectively (P=0.013). Cox regression analysis revealed baseline platelet count >276×10(9)/L was an independent unfavorable factor for DFS of adjuvant chemotherapy in colorectal cancer (HR=1.865, 95% CI: 1.108-3.141, P=0.019).
  
  
  CONCLUSIONS
  Colorectal cancer patients receiving adjuvant chemotherapy with baseline platelet count >276×10(9)/L have worse prognosis.
authors.affiliation: Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China. yswei2004@126.com.
authors.forename: Yisheng
authors.initials: Y
authors.lastname: Wei
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Liang
authors.forename: Chuyuan
authors.initials: C
authors.lastname: Hong
authors.forename: Diteng
authors.initials: D
authors.lastname: Luo
authors.forename: Zizhi
authors.initials: Z
authors.lastname: Cai
authors.forename: Huajie
authors.initials: H
authors.lastname: Guan
authors.forename: Zicheng
authors.initials: Z
authors.lastname: Zeng
authors.forename: Ziyun
authors.initials: Z
authors.lastname: Yang
authors.forename: Pan
authors.initials: P
authors.lastname: Luo
authors.forename: Zeyu
authors.initials: Z
authors.lastname: Tan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms; D015179:Colorectal Neoplasms; D018572:Disease-Free Survival; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds; D010976:Platelet Count; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil